Key facts
- This page summarizes Eric Warren's Form 4 filing for Esperion Therapeutics, Inc. (ESPR).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 20 Jul 2022, 16:27.
Eric Warren - 19 Jul 2022 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- ESPR
- Reported as of
- 19 Jul 2022
- Net transaction value
- -$2,837
- SEC form
- 4
- Accepted by SEC
- 20 Jul 2022, 16:27:07 UTC
- Prior SEC filing
- 21 Jun 2022
- Next SEC filing
- 18 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sheldon L. Koenig
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Warren filed Form 4 for Esperion Therapeutics, Inc. (ESPR) on 20 Jul 2022.
Change
- Previous filing in this sequence was filed on 21 Jun 2022.
- Current net transaction value: -$2,837.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ESPR
transaction
Common Stock
Sale
- Transaction value
- $2,837
- Shares
- -431
- Change %
- -0.8%
- Price
- $6.58
- Shares after
- 53,223
- Date
- 19 Jul 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Shares were sold to satisfy tax obligation on quarterly vested shares of restricted stock units.